Mirabegron*
-
API Product :
Mirabegron*
-
CEP :
-
-
WCC :
-
-
Therapeutic Use :
Urologicals
-
Originator :
ASTELLAS PHARMA US
-
CAS No. :
223673-61-8
-
Trade Name. :
MYRBETRIQ
-
Molecular Weight :
396.506 g/mol
-
Molecular Formula :
ASTELLAS PHARMA US
Application
Mirabegron reduces muscle spasms of the bladder and urinary tract. Mirabegron is used to treat overactive bladder with symptoms of frequent or urgent urination and urinary incontinence. Mirabegron may also be used for purposes not listed in this medication guide
General Description
Mirabegron (trade name Myrbetriq and Betmiga) is a medication for the treatment of overactive bladder.[2] It was developed by Astellas Pharma and was approved in the United States in July 2012.[3] Mirabegron activates the ?3 adrenergic receptor in the detrusor muscle in the bladder, which leads to muscle relaxation and an increase in bladder capacity.[4]